JP2018521964A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018521964A5 JP2018521964A5 JP2017558434A JP2017558434A JP2018521964A5 JP 2018521964 A5 JP2018521964 A5 JP 2018521964A5 JP 2017558434 A JP2017558434 A JP 2017558434A JP 2017558434 A JP2017558434 A JP 2017558434A JP 2018521964 A5 JP2018521964 A5 JP 2018521964A5
- Authority
- JP
- Japan
- Prior art keywords
- concentration
- composition
- rhtpp1
- item
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 127
- 201000010099 disease Diseases 0.000 claims description 48
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 48
- 238000009472 formulation Methods 0.000 claims description 40
- 101000799476 Homo sapiens Tripeptidyl-peptidase 1 Proteins 0.000 claims description 37
- 230000006870 function Effects 0.000 claims description 27
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 22
- 230000007423 decrease Effects 0.000 claims description 21
- 230000007659 motor function Effects 0.000 claims description 19
- 230000035790 physiological processes and functions Effects 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 claims description 11
- 229940052299 calcium chloride dihydrate Drugs 0.000 claims description 11
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 claims description 11
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 239000001103 potassium chloride Substances 0.000 claims description 11
- 235000011164 potassium chloride Nutrition 0.000 claims description 11
- 230000007937 eating Effects 0.000 claims description 10
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 claims description 10
- 230000000926 neurological effect Effects 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 229940052354 dibasic sodium phosphate heptahydrate Drugs 0.000 claims description 6
- PYLIXCKOHOHGKQ-UHFFFAOYSA-L disodium;hydrogen phosphate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O PYLIXCKOHOHGKQ-UHFFFAOYSA-L 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 230000000007 visual effect Effects 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
- 238000007913 intrathecal administration Methods 0.000 claims description 2
- 238000007914 intraventricular administration Methods 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 101710087078 Dipeptidyl peptidase 1 Proteins 0.000 claims 1
- 102100029921 Dipeptidyl peptidase 1 Human genes 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 69
- 230000004438 eyesight Effects 0.000 description 16
- 210000004556 brain Anatomy 0.000 description 14
- 238000011010 flushing procedure Methods 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 230000009467 reduction Effects 0.000 description 7
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 6
- 206010060860 Neurological symptom Diseases 0.000 description 5
- 229910000397 disodium phosphate Inorganic materials 0.000 description 5
- 235000019800 disodium phosphate Nutrition 0.000 description 5
- 210000004884 grey matter Anatomy 0.000 description 5
- 238000007917 intracranial administration Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 206010010904 Convulsion Diseases 0.000 description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 208000033528 CLN2 disease Diseases 0.000 description 3
- 229920002160 Celluloid Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 description 1
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 description 1
- 101710167374 Peptidase 1 Proteins 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000004377 improving vision Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- -1 sodium phosphate dibasic decahydrate Chemical class 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021131875A JP7421520B2 (ja) | 2015-05-08 | 2021-08-13 | Ｔｐｐ１配合物及びｃｌｎ２疾患を治療するための方法 |
| JP2024003133A JP2024026739A (ja) | 2015-05-08 | 2024-01-12 | Ｔｐｐ１配合物及びｃｌｎ２疾患を治療するための方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562158789P | 2015-05-08 | 2015-05-08 | |
| US62/158,789 | 2015-05-08 | ||
| US201662300171P | 2016-02-26 | 2016-02-26 | |
| US62/300,171 | 2016-02-26 | ||
| PCT/US2016/031074 WO2016182862A1 (en) | 2015-05-08 | 2016-05-05 | Tpp1 formulations and methods for treating cln2 disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021131875A Division JP7421520B2 (ja) | 2015-05-08 | 2021-08-13 | Ｔｐｐ１配合物及びｃｌｎ２疾患を治療するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018521964A JP2018521964A (ja) | 2018-08-09 |
| JP2018521964A5 true JP2018521964A5 (enExample) | 2019-06-13 |
| JP6931330B2 JP6931330B2 (ja) | 2021-09-01 |
Family
ID=57222195
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017558434A Active JP6931330B2 (ja) | 2015-05-08 | 2016-05-05 | Ｔｐｐ１配合物及びｃｌｎ２疾患を治療するための方法 |
| JP2021131875A Active JP7421520B2 (ja) | 2015-05-08 | 2021-08-13 | Ｔｐｐ１配合物及びｃｌｎ２疾患を治療するための方法 |
| JP2024003133A Pending JP2024026739A (ja) | 2015-05-08 | 2024-01-12 | Ｔｐｐ１配合物及びｃｌｎ２疾患を治療するための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021131875A Active JP7421520B2 (ja) | 2015-05-08 | 2021-08-13 | Ｔｐｐ１配合物及びｃｌｎ２疾患を治療するための方法 |
| JP2024003133A Pending JP2024026739A (ja) | 2015-05-08 | 2024-01-12 | Ｔｐｐ１配合物及びｃｌｎ２疾患を治療するための方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US10279015B2 (enExample) |
| EP (2) | EP3294345B1 (enExample) |
| JP (3) | JP6931330B2 (enExample) |
| KR (1) | KR102375051B1 (enExample) |
| CN (2) | CN114225018A (enExample) |
| AU (1) | AU2016262434B2 (enExample) |
| CA (1) | CA2984448A1 (enExample) |
| CL (1) | CL2017002825A1 (enExample) |
| DK (1) | DK3294345T3 (enExample) |
| ES (1) | ES2968375T3 (enExample) |
| FI (1) | FI3294345T3 (enExample) |
| HR (2) | HRP20171905B1 (enExample) |
| HU (1) | HUE065649T2 (enExample) |
| IL (3) | IL299024B2 (enExample) |
| LT (1) | LT3294345T (enExample) |
| MX (1) | MX2017014204A (enExample) |
| PL (1) | PL3294345T3 (enExample) |
| PT (1) | PT3294345T (enExample) |
| RS (1) | RS65101B1 (enExample) |
| RU (1) | RU2733464C2 (enExample) |
| SI (1) | SI3294345T1 (enExample) |
| SM (1) | SMT202400026T1 (enExample) |
| TW (1) | TWI752907B (enExample) |
| WO (1) | WO2016182862A1 (enExample) |
| ZA (1) | ZA201707373B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI752907B (zh) * | 2015-05-08 | 2022-01-21 | 美商拜奧馬林製藥公司 | 用於治療cln2疾病之tpp1調配物及方法 |
| EP3607320A4 (en) | 2017-04-03 | 2021-04-21 | The Regents of the University of California | COMPOSITIONS AND METHODS OF DIAGNOSING Pancreatic Cancer |
| WO2019060298A1 (en) | 2017-09-19 | 2019-03-28 | Neuroenhancement Lab, LLC | METHOD AND APPARATUS FOR NEURO-ACTIVATION |
| US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
| US12280219B2 (en) | 2017-12-31 | 2025-04-22 | NeuroLight, Inc. | Method and apparatus for neuroenhancement to enhance emotional response |
| US11318277B2 (en) | 2017-12-31 | 2022-05-03 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
| US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
| CA3112564A1 (en) | 2018-09-14 | 2020-03-19 | Neuroenhancement Lab, LLC | System and method of improving sleep |
| US11786694B2 (en) | 2019-05-24 | 2023-10-17 | NeuroLight, Inc. | Device, method, and app for facilitating sleep |
| US20220381784A1 (en) * | 2019-06-07 | 2022-12-01 | The Regents Of The University Of California | Systems comprising substrates and methods of using the same for detection of pancreatic cancers |
| HRP20240871T1 (hr) * | 2019-08-29 | 2024-10-11 | Biomarin Pharmaceutical Inc. | Postupci liječenja cln2 bolesti kod pedijatrijskih subjekata |
| IT201900023142A1 (it) * | 2019-12-05 | 2021-06-05 | Sifi Spa | Composizione topica oculare contenente metaboliti della fermentazione di lactobacillus |
| US20230060797A1 (en) * | 2021-09-02 | 2023-03-02 | Jcr Pharmaceuticals Co., Ltd. | Therapeutic compound for neuronal ceroid lipofuscinosis |
| CN117731312A (zh) | 2022-09-13 | 2024-03-22 | 上海联影医疗科技股份有限公司 | 一种医学图像的扫描方法和系统 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6302685B1 (en) | 1997-09-16 | 2001-10-16 | University Of Medicine And Dentistry Of New Jersey | Human lysosomal protein and methods of its use |
| US20020006400A1 (en) | 2000-05-11 | 2002-01-17 | Peter Lobel | Recombinant human CLN2 protein and methods of its production and use |
| MXPA03010341A (es) * | 2001-05-18 | 2004-03-10 | Solvay Pharm Gmbh | Uso de compuestos con actividad inhibitoria de epn/mp combinada en la preparacion de medicamentos. |
| AU2002362436A1 (en) * | 2001-10-03 | 2003-04-14 | Rigel Pharmaceuticals, Inc. | Modulators of lymphocyte activation and migration |
| CA2388659A1 (en) * | 2002-05-31 | 2003-11-30 | Mcgill University | Phospholipase a2 expression and activity and use thereof for diagnosis, prognostication, prevention and treatment of neural inflammatory and demyelinating disease |
| US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| WO2008049058A2 (en) | 2006-10-18 | 2008-04-24 | Cornell Research Foundation, Inc. | Cln2 treatment of alzheimer's disease |
| CA2721135A1 (en) | 2007-06-13 | 2008-12-24 | Wayne State University Board Of Governors | A zwitterion solution for low-volume therapeutic delivery |
| EP2333074A1 (en) * | 2009-12-14 | 2011-06-15 | Robert Steinfeld | Substances and methods for the treatment of lysosmal storage diseases |
| WO2012015910A2 (en) * | 2010-07-28 | 2012-02-02 | Allon Therapeutics Inc. | Use of adnf polypeptides for treating neurodegenerative diseases |
| EP2723359A4 (en) * | 2011-06-24 | 2015-03-11 | Amylin Pharmaceuticals Llc | METHOD FOR THE TREATMENT OF DIABETES WITH THE HELP OF DELAYED RELEASED FORMULATIONS FROM GLP-1 RECEPTOR AGONISTS |
| US20150000936A1 (en) * | 2011-12-13 | 2015-01-01 | Schlumberger Technology Corporation | Energization of an element with a thermally expandable material |
| US20140377244A1 (en) | 2011-12-23 | 2014-12-25 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
| KR102262882B1 (ko) * | 2012-11-27 | 2021-06-10 | 바이오마린 파머수티컬 인크. | 표적화된 치료적 리소좀 효소 융합 단백질들 및 그들의 용도들 |
| US9750712B2 (en) * | 2012-12-07 | 2017-09-05 | Rush University Medical Center | Composition and method for treating neuronal ceroid lipofuscinosis |
| DK3024497T3 (da) * | 2013-07-26 | 2021-04-12 | Univ Iowa Res Found | Fremgangsmåder og præparater til behandling af hjernesygdomme |
| TWI752907B (zh) * | 2015-05-08 | 2022-01-21 | 美商拜奧馬林製藥公司 | 用於治療cln2疾病之tpp1調配物及方法 |
-
2016
- 2016-04-27 TW TW105113155A patent/TWI752907B/zh active
- 2016-05-05 IL IL299024A patent/IL299024B2/en unknown
- 2016-05-05 MX MX2017014204A patent/MX2017014204A/es unknown
- 2016-05-05 WO PCT/US2016/031074 patent/WO2016182862A1/en not_active Ceased
- 2016-05-05 RS RS20240067A patent/RS65101B1/sr unknown
- 2016-05-05 AU AU2016262434A patent/AU2016262434B2/en active Active
- 2016-05-05 RU RU2017142727A patent/RU2733464C2/ru active
- 2016-05-05 HR HRP20171905AA patent/HRP20171905B1/hr active IP Right Grant
- 2016-05-05 CA CA2984448A patent/CA2984448A1/en active Pending
- 2016-05-05 HR HRP20240050TT patent/HRP20240050T1/hr unknown
- 2016-05-05 EP EP16793229.2A patent/EP3294345B1/en active Active
- 2016-05-05 SM SM20240026T patent/SMT202400026T1/it unknown
- 2016-05-05 ES ES16793229T patent/ES2968375T3/es active Active
- 2016-05-05 PL PL16793229.2T patent/PL3294345T3/pl unknown
- 2016-05-05 PT PT167932292T patent/PT3294345T/pt unknown
- 2016-05-05 KR KR1020177032973A patent/KR102375051B1/ko active Active
- 2016-05-05 SI SI201631792T patent/SI3294345T1/sl unknown
- 2016-05-05 CN CN202210014711.9A patent/CN114225018A/zh active Pending
- 2016-05-05 US US15/147,485 patent/US10279015B2/en active Active
- 2016-05-05 DK DK16793229.2T patent/DK3294345T3/da active
- 2016-05-05 CN CN201680025984.6A patent/CN107847615B/zh active Active
- 2016-05-05 EP EP23204139.2A patent/EP4327873A3/en active Pending
- 2016-05-05 JP JP2017558434A patent/JP6931330B2/ja active Active
- 2016-05-05 HU HUE16793229A patent/HUE065649T2/hu unknown
- 2016-05-05 LT LTEPPCT/US2016/031074T patent/LT3294345T/lt unknown
- 2016-05-05 FI FIEP16793229.2T patent/FI3294345T3/fi active
-
2017
- 2017-10-29 IL IL255307A patent/IL255307B/en active IP Right Grant
- 2017-10-30 ZA ZA2017/07373A patent/ZA201707373B/en unknown
- 2017-11-08 CL CL2017002825A patent/CL2017002825A1/es unknown
-
2019
- 2019-03-28 US US16/368,091 patent/US10758598B2/en active Active
-
2020
- 2020-04-12 IL IL273913A patent/IL273913B2/en unknown
- 2020-07-28 US US16/941,454 patent/US11229687B2/en active Active
-
2021
- 2021-08-13 JP JP2021131875A patent/JP7421520B2/ja active Active
-
2024
- 2024-01-12 JP JP2024003133A patent/JP2024026739A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018521964A5 (enExample) | ||
| JP7421520B2 (ja) | Ｔｐｐ１配合物及びｃｌｎ２疾患を治療するための方法 | |
| CA2814057C (en) | Intravenous composition comprising paracetamol and ibuprofen | |
| RU2018121615A (ru) | Модуляторы активности комплемента | |
| JP2015520188A5 (enExample) | ||
| JP2016514132A5 (enExample) | ||
| EP3347032B1 (en) | Terlipressin for the treatment of ascites due to liver cirrhosis administered as a continuous infusion | |
| US10821126B2 (en) | Agent for treating retinopathy | |
| US20050187290A1 (en) | Compositions intended for the treatment of peripheral neuropathies, preparation thereof and uses of same | |
| JP2003159028A (ja) | 花粉症治療用食品 | |
| WO2020207344A1 (zh) | 匹莫齐特和甲氨蝶呤的药物组合及其应用 | |
| JPH09506603A (ja) | 多発性硬化症治療でのペントキシフィリンの使用 | |
| JP7228895B2 (ja) | 敗血症の予防又は治療用組成物 | |
| US20140100165A1 (en) | Prevention of kidney injury or disease | |
| WO2025081188A1 (en) | Combination compositions and methods to treat polycystic kidney disease | |
| HK40107015A (en) | Tpp1 formulations and methods for treating cln2 disease | |
| WO2016133069A1 (ja) | 心不全の予防又は治療のための医薬 | |
| JPS5920221A (ja) | レイノ−症状の改善・治療剤 | |
| WO2016139740A1 (ja) | 肝線維化改善剤 | |
| Suzuki | Antithymocyte-globulin | |
| Hojer | Allopurinol/metformin | |
| Over | Can DPP-4 inhibitors be used safely along with metformin in the elderly population? | |
| WO2014150318A1 (en) | Therapeutic agent for enhancing mitochondrial function |